Signature Global Faces Financial Setback but Sets Ambitious Sales Goals

Signature Global, a leading real estate developer in India, reported a substantial net loss for the July-September FY26 period. The company's income dropped significantly compared to the previous year. Despite this, Signature Global plans strategic land acquisitions to meet ambitious pre-sales targets and maintain a positive market outlook.


Devdiscourse News Desk | New Delhi | Updated: 08-11-2025 10:56 IST | Created: 08-11-2025 10:56 IST
Signature Global Faces Financial Setback but Sets Ambitious Sales Goals
This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.
  • Country:
  • India

Leading Indian real estate developer Signature Global reported a consolidated net loss of Rs 46.86 crore for the July-September quarter of FY26, attributing the figure to reduced income streams.

Contrasting this loss, the company had posted a net profit of Rs 4.15 crore during the same period last year as total income plummeted to Rs 372.51 crore from Rs 777.42 crore year-over-year. Moreover, in the first half of the fiscal year, Signature Global displayed a net loss of Rs 12.42 crore, diverging from a net profit of Rs 10.94 crore in the equivalent previous period, despite a rise in total income to Rs 1,270.86 crore.

CEO Pradeep Aggarwal remains confident in short-term strategy, stating forthcoming plans for substantial housing launches aided by land acquisitions and a partnership with IFC, which will drive the company towards meeting a pre-sales target of Rs 12,500 crore, aiming to launch Rs 14,000 crore worth of homes by next March.

TRENDING

DevShots

Latest News

OPINION / BLOG / INTERVIEW

Cyber-resilient electric mobility: AI shields EV charging stations from cyber-attacks

AI can decode medical records with near-human accuracy

New AI model could save historic monuments before they crumble

How AI systems must prove trust, transparency and reliability before clinical use

Connect us on

LinkedIn Quora Youtube RSS
Give Feedback